Analyst
Berenberg
Equibles does not estimate personal net worth.
Kerry Holford is recorded as Analyst at Berenberg. Kerry Holford has spoken on 8 earnings calls across 5 companies, most recently for Novo Nordisk A S on November 4, 2026. Those appearances were for Novartis AG (NVS), Novo Nordisk A S (NVO), ZEALAND PHARMA A/S, Zealand Pharma A/S (ZLDPF) and ELI LILLY & Co (LLY). The companies whose calls Kerry Holford spoke on are classified in the Healthcare sector.
“And thank you again also to Carsten for the many years of interactions. I will finish again on bridge. Just linking to that question in a way with regard to commercial opt-ins.”
“I wonder, Vaz, if you could give us a little bit more insight into the plans post-harbour. Will you run another Phase 3? Are you considering different endpoints and updates on the timelines?”
“Carlson, I think you said around 35% of that injectable regarding demand is now by the cash channel.”
“Question from me on Kitsikali, just on the IP. The extension that you've been granted related to paediatric exclusivity, can you confirm now that that COVID-19 expiry is May 2032, and in the context of your earlier settlements of generic players, is that when we should now be assuming generic market entry?”
Berenberg
Analyst
Source not stated
NVS
Drug Manufacturers - General · Healthcare
NVO
Drug Manufacturers - General · Healthcare
ZEALAND PHARMA A/S
Biotechnology · Healthcare
ZLDPF
Biotechnology · Healthcare
LLY
Drug Manufacturers - General · Healthcare
H1 Financial Results / Interim Report First Half 2026
ZEALAND PHARMA A/S
